ClinicalTrials.gg
CompletedNCT01181895Updated Nov 8, 2017Results posted

Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma

A Phase 3 interventional study of Vilanterol and Salmeterol Inhalation Powder in Asthma, sponsored by GlaxoSmithKline. Completed at 34 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-11-08.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
348
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing vilanterol in Asthma — none open to participants now, 2 under way, 2 of them phase 3. vilanterol · Asthma.

Enrollment
8th of 30
348 · median 69
Started
2010
with 9 others
Phase 3
14 of 30
none open now
Registered
8th of 30
by date
Lead sponsor
27 of 30
GlaxoSmithKline

Among the 30 studies testing vilanterol in Asthma, this one is the 8th largest by enrollment, is one of 10 that started in 2010, is one of 14 in phase 3, and was the 8th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 30 studies testing vilanterol in Asthma is open now. The open studies under Asthma, anywhere →

About vilanterol

vilanterol: first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies testing vilanterol in Asthma as a file.
02

Study summary

The objective of this study is to evaluate the efficacy and safety of vilanterol inhalation powder administered once daily in the evening in adolescent and adult subjects 12 years of age and older with persistent asthma over a 12-week treatment period.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatient at least 12 years of age
  • Both genders; females of must be willing to use method
  • Clinical diagnosis of asthma for ≥12 weeks
  • Best pre-bronchodilator of 40%-90% predicted
  • Reversibility of FEV1 of at least 12% and 200mls
  • Current asthma therapy that include an inhaled for at least 12 weeks prior to 1st visit
  • Ability to use replace current short-acting rescue treatment with albuterol and ability to withhold albuterol use for at least 6 hours prior to study visits

Exclusion criteria

Exclusion Criteria:

  • History of life-threatening asthma
  • Respiratory infection within last 4 weeks leading to change in asthma management
  • Asthma exacerbation within last 3 months
  • Concurrent respiratory disease or other disease that would confound study participation or affect subject safety
  • Allergies to study drugs, study drugs' , or medications related to study drugs
  • Taking another medication or medication prohibited for use during the study.
  • Previous participation in a vilanterol (GW642444) study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
348 participants (actual)

Study arms

  • Experimental
    Vilanterol

    Vilanterol inhalation powder once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks

    Drug: Vilanterol · Drug: Placebo Inhalation Powder Diskus

  • Active comparator
    Salmeterol

    Placebo inhalation powder via NDPI once daily + Salmeterol inhalation powder twice daily for 12 weeks

    Drug: Salmeterol Inhalation Powder · Drug: Placebo Inhalation Powder NDPI

  • Placebo comparator
    Placebo

    Placebo inhalation powder via NDPI once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks

    Drug: Placebo Inhalation Powder NDPI · Drug: Placebo Inhalation Powder Diskus

Interventions

  • Vilanterol inhalation powder inhaled orally once daily for 12 weeks

  • DrugSalmeterol Inhalation Powder

    Salmeterol inhalation powder inhaled orally twice daily for 12 weeks

  • DrugPlacebo Inhalation Powder NDPI

    Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler

  • DrugPlacebo Inhalation Powder Diskus

    Placebo inhalation powder inhaled orally twice daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at Week 12

    FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second. The weighted mean is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, and 30 minutes (min) and at 1, 2, 3, 4, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, respectively, at Week 12. The Baseline value was the Day 1 pre-dose FEV1 measurement. Change from Baseline is calculated as the weighted mean 0-24 hour FEV1 (Liters) at Week 12 minus the Baseline value. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline FEV1, region, sex, age, and treatment.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period

    The time span during which the participants did not have to take any rescue bronchodilator (medication intended to relieve symptoms immediately) was considered to be a rescue-free period. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization). Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

    Time frame: Baseline and Weeks 1-12

  2. Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period

    Participants who were symptom free for 24-hour periods during the12-week treatment period were assessed. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization). Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

    Time frame: Baseline and Weeks 1-12

  3. Change From Baseline in Individual Serial FEV1 Assessments at the End of the 12-week Treatment Period, Including the 12-hour and 24-hour Time Points

    FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second. The individual serial FEV1 is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, 30, and 60 minutes (min) and 2, 3, 5, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, relatively, on Treatment Day 84 (Week 12). The Baseline value was the Day 1 pre-dose FEV1 measurement. Change from Baseline was calculated as the value of the individual serial FEV1 taken at Week 12 minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment. Analysis was performed separately for each planned time point.

    Time frame: Baseline and Week 12

  4. Change From Baseline in Daily Trough (Pre-dose and Pre-rescue Bronchodilator) PM (Evening) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period

    PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. The Baseline value is the average value of the last 7 days of daily PM PEF prior to randomization. Change from Baseline in trough PM PEF was calculated as the averaged value of all daily PM PEF for Week 1 to Week 12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

    Time frame: Baseline and Weeks 1-12

  5. Change From Baseline in Daily AM (Morning) PEF Averaged Over the 12-week Treatment Period

    PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. The Baseline value is the average value of the last 7 days of daily AM PEF prior to randomization. Change from Baseline in trough AM PEF was calculated as the averaged value of all daily AM PEF for Weeks 1 to Week 12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

    Time frame: Baseline and Weeks 1-12

  6. Number of Participants With the Indicated Time to an Increase of >=12% and >=200 Milliliters (mL) Above Baseline in FEV1 on Day 1 and Day 84 (0-2 Hours)

    The number of participants with a \>=12% and \>=200 mL increase from Baseline in FEV1 (the maximal amount of air that can be forcefully exhaled in one second) was evaluated on Day 1 and Week 12 for the time to a \>=12% increase from Baseline (at the 5 minutes (min), 15 min, 30 min, 1hour (hr), and 2 hr nominal time points. Participants who did not achieve a \>=12% and \>=200 mL increase from Baseline in FEV1 over this time period were considered censored.

    Time frame: Day 1 and Week 12

  7. Number of Participants With the Indicated Global Assessment of Change Questionnaire Responses at the End of Week 4 and Week 12

    At the end of Week 4 and Week 12, the Global Assessment of Change Questionnaire, which assesses changes in asthma symptoms and rescue medication use, was completed by participants using the following scale: asthma symptom (AS) change: much better, somewhat better, a little better, the same, a little worse, somewhat worse, much worse; rescue medication use (RMU): much less often , somewhat less often , a little less often , the same , a little more often , somewhat more often , much more often.

    Time frame: Week 4 and Week 12

07

Results

Posted Aug 26, 2013

Participant flow

347 participants (par.) were randomized to treatment; all 347 were included in the Intent-to-Treat (ITT) Population. One par. was not randomized but received treatment in error. This par. was not included in the ITT Population and is thus not captured in the Participant Flow module. This par. is categorized as being enrolled in the study (n=348).

Participant flow — Overall Study
MilestonePlaceboVilanteral 25 µg ODSalmeterol 50 µg BID
Started116115116
Completed9910198
Not completed171418
Withdrew: Adverse event311
Withdrew: Lack of efficacy899
Withdrew: Protocol violation210
Withdrew: Lost to follow-up012
Withdrew: Investigator discretion121
Withdrew: Withdrawal by subject305

Outcome measures

PrimaryChange From Baseline in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at Week 12

FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second. The weighted mean is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, and 30 minutes (min) and at 1, 2, 3, 4, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, respectively, at Week 12. The Baseline value was the Day 1 pre-dose FEV1 measurement. Change from Baseline is calculated as the weighted mean 0-24 hour FEV1 (Liters) at Week 12 minus the Baseline value. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline FEV1, region, sex, age, and treatment.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Liters
Change From Baseline in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at Week 12
LitersPlaceboVilanteral 25 µg ODSalmeterol 50 µg BID
Change From Baseline in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at Week 120.289 ± 0.04290.359 ± 0.04160.283 ± 0.0419
Statistical analysis
  • Placebo vs Vilanteral 25 µg OD · ANCOVA · p = 0.244 (P-value for the adjusted treatment difference for Vilanterol 25 µg OD versus Placebo.) · Mean difference (final values): 0.070 · 95% CI -0.048 to 0.188The estimated value represents the adjusted treatment difference in the weighted mean 0-24 hour FEV1 (Liters) at Week 12 for Vilanterol 25 µg OD versus Placebo.
  • Placebo vs Salmeterol 50 µg BID · ANCOVA · p = 0.926 (P-value for the adjusted treatment difference for Salmetarol 50 µg BID versus Placebo.) · Mean difference (final values): -0.006 · 95% CI -0.124 to 0.113The estimated value represents the adjusted treatment difference in the weighted mean 0-24 hour FEV1 (Liters) at Week 12 for Salmeterol 50 µg BID versus Placebo.
SecondaryChange From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period

The time span during which the participants did not have to take any rescue bronchodilator (medication intended to relieve symptoms immediately) was considered to be a rescue-free period. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization). Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

Time frame:
Baseline and Weeks 1-12
Reported as:
Least squares mean · Percentage of rescue-free 24-hr periods
Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period
Percentage of rescue-free 24-hr periodsPlaceboVilanteral 25 µg ODSalmeterol 50 µg BID
Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period14.6 ± 2.7121.7 ± 2.6822.9 ± 2.72
SecondaryChange From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period

Participants who were symptom free for 24-hour periods during the12-week treatment period were assessed. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization). Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

Time frame:
Baseline and Weeks 1-12
Reported as:
Least squares mean · Percentage of symptom-free 24-hr periods
Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period
Percentage of symptom-free 24-hr periodsPlaceboVilanteral 25 µg ODSalmeterol 50 µg BID
Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period12.7 ± 2.5819.4 ± 2.5519.5 ± 2.59
SecondaryChange From Baseline in Individual Serial FEV1 Assessments at the End of the 12-week Treatment Period, Including the 12-hour and 24-hour Time Points

FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second. The individual serial FEV1 is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, 30, and 60 minutes (min) and 2, 3, 5, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, relatively, on Treatment Day 84 (Week 12). The Baseline value was the Day 1 pre-dose FEV1 measurement. Change from Baseline was calculated as the value of the individual serial FEV1 taken at Week 12 minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment. Analysis was performed separately for each planned time point.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Liters
Change From Baseline in Individual Serial FEV1 Assessments at the End of the 12-week Treatment Period, Including the 12-hour and 24-hour Time Points
LitersPlaceboVilanteral 25 µg ODSalmeterol 50 µg BID
Predose, n=97,104,1010.302 ± 0.04460.272 ± 0.04300.233 ± 0.0437
5 min, n=95,100,980.313 ± 0.04500.301 ± 0.04380.214 ± 0.0443
15 min, n=96, 101, 990.308 ± 0.04500.324 ± 0.04390.257 ± 0.0444
30 min, n=,96,101,1000.322 ± 0.04430.344 ± 0.04320.272 ± 0.0435
60 min, n=96, 101, 1000.336 ± 0.04450.352 ± 0.04330.296 ± 0.0437
2 hours, n=96, 100, 990.313 ± 0.04550.369 ± 0.04460.335 ± 0.0449
3 hours, n=96, 101, 1000.304 ± 0.04550.374 ± 0.04440.316 ± 0.0447
4 hours, n=96, 101, 1000.311 ± 0.04500.359 ± 0.04380.293 ± 0.0441
5 hours, n=96, 100, 1000.292 ± 0.04550.368 ± 0.04450.279 ± 0.0447
11 hours, n=94, 99, 960.195 ± 0.05080.312 ± 0.04940.179 ± 0.0505
12 hours, n=93,98,950.250 ± 0.04770.341 ± 0.04650.217 ± 0.0473
12.5 hours, n=96, 97, 980.270 ± 0.04460.337 ± 0.04440.282 ± 0.0443
13 hours, 96, 98, 1000.312 ± 0.04480.341 ± 0.04420.304 ± 0.0440
14 hours, n=95, 99, 990.341 ± 0.04450.401 ± 0.04360.359 ± 0.0437
16 hours, n=95, 98, 970.364 ± 0.04640.371 ± 0.04570.357 ± 0.0461
20 hours, n= 94, 101, 990.318 ± 0.04850.371 ± 0.04670.296 ± 0.0473
23 hours, 94, 101, 990.310 ± 0.04560.345 ± 0.04400.271 ± 0.0446
24 hours, n= 95, 101, 1000.301 ± 0.04450.330 ± 0.04320.275 ± 0.0435
SecondaryChange From Baseline in Daily Trough (Pre-dose and Pre-rescue Bronchodilator) PM (Evening) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. The Baseline value is the average value of the last 7 days of daily PM PEF prior to randomization. Change from Baseline in trough PM PEF was calculated as the averaged value of all daily PM PEF for Week 1 to Week 12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

Time frame:
Baseline and Weeks 1-12
Reported as:
Least squares mean · Liters per minute (L/min)
Change From Baseline in Daily Trough (Pre-dose and Pre-rescue Bronchodilator) PM (Evening) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period
Liters per minute (L/min)PlaceboVilanteral 25 µg ODSalmeterol 50 µg BID
Change From Baseline in Daily Trough (Pre-dose and Pre-rescue Bronchodilator) PM (Evening) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period11.0 ± 3.1524.9 ± 3.1418.8 ± 3.17
SecondaryChange From Baseline in Daily AM (Morning) PEF Averaged Over the 12-week Treatment Period

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. The Baseline value is the average value of the last 7 days of daily AM PEF prior to randomization. Change from Baseline in trough AM PEF was calculated as the averaged value of all daily AM PEF for Weeks 1 to Week 12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

Time frame:
Baseline and Weeks 1-12
Reported as:
Least squares mean · Liters per minute (L/min)
Change From Baseline in Daily AM (Morning) PEF Averaged Over the 12-week Treatment Period
Liters per minute (L/min)PlaceboVilanteral 25 µg ODSalmeterol 50 µg BID
Change From Baseline in Daily AM (Morning) PEF Averaged Over the 12-week Treatment Period14.2 ± 3.2528.0 ± 3.2423.6 ± 3.27
SecondaryNumber of Participants With the Indicated Time to an Increase of >=12% and >=200 Milliliters (mL) Above Baseline in FEV1 on Day 1 and Day 84 (0-2 Hours)

The number of participants with a \>=12% and \>=200 mL increase from Baseline in FEV1 (the maximal amount of air that can be forcefully exhaled in one second) was evaluated on Day 1 and Week 12 for the time to a \>=12% increase from Baseline (at the 5 minutes (min), 15 min, 30 min, 1hour (hr), and 2 hr nominal time points. Participants who did not achieve a \>=12% and \>=200 mL increase from Baseline in FEV1 over this time period were considered censored.

Time frame:
Day 1 and Week 12
Reported as:
Number · Participants
Number of Participants With the Indicated Time to an Increase of >=12% and >=200 Milliliters (mL) Above Baseline in FEV1 on Day 1 and Day 84 (0-2 Hours)
ParticipantsPlaceboVilanteral 25 µg ODSalmeterol 50 µg BID
Day 1, 5 min, n=113, 115, 116233318
Day 1, 15 min, n=113, 115, 11621111
Day 1, 30 min, n=113, 115, 11163813
Day 1, 1 hr, n=113, 115, 116376
Day 1, 2 hr, n=113, 115, 1165611
Day 1, Censored, n=113, 115, 116775057
Week 12, 5 min, n=96, 101, 100394230
Week 12, 15 min, n=96, 101, 100627
Week 12, 30 min, n=96, 101, 100228
Week 12, 1 hr, n=96, 101, 100145
Week 12, 2 hr, n=96, 101, 100374
Week 12, Censored, n=96, 101, 100454446
SecondaryNumber of Participants With the Indicated Global Assessment of Change Questionnaire Responses at the End of Week 4 and Week 12

At the end of Week 4 and Week 12, the Global Assessment of Change Questionnaire, which assesses changes in asthma symptoms and rescue medication use, was completed by participants using the following scale: asthma symptom (AS) change: much better, somewhat better, a little better, the same, a little worse, somewhat worse, much worse; rescue medication use (RMU): much less often , somewhat less often , a little less often , the same , a little more often , somewhat more often , much more often.

Time frame:
Week 4 and Week 12
Reported as:
Number · Participants
Number of Participants With the Indicated Global Assessment of Change Questionnaire Responses at the End of Week 4 and Week 12
ParticipantsPlaceboVilanteral 25 µg ODSalmeterol 50 µg BID
Week 4, AS: Much better, n=110, 109, 110253734
Week 4, AS: Somewhat better, n=110, 109, 110354334
Week 4, AS: A little better, n=110, 109, 110241421
Week 4, AS: The same, n=110, 109, 110171316
Week 4, AS: A little worse, n=110, 109, 110613
Week 4, AS: Somewhat worse, n=110, 109, 110202
Week 4, AS: Much worse, n=110, 109, 110110
Week 4, RMU: Much less often, n=110, 109, 110183328
Week 4, RMU: Somewhat less often, n=110, 109, 110403136
Week 4, RMU: A little less often, n=110, 109, 110182320
Week 4, RMU: The same, n=110, 109, 110261817
Week 4, RMU: A little more often, n=110, 109, 110437
Week 4, RMU: Somewhat more often, n=110, 109, 110202
Week 4, RMU: Much more often, n=110, 109, 110210
Week 12, AS: Much better, n=100, 105, 101315235
Week 12, AS: Somewhat better, n=100, 105, 101353134
Week 12, AS: A little better, n=100, 105, 10113916
Week 12, AS: The same, n=100, 105, 10112911
Week 12, AS: A little worse, n=100, 105, 101424
Week 12, AS: Somewhat worse, n=100, 105, 101411
Week 12, AS: Much worse, n=100, 105, 101110
Week 12, RMU: Much less often, n=100, 105, 101254032
Week 12, RMU: Somewhat less often, n=100, 105, 101313229
Week 12, RMU: A little less often, n=100, 105, 101131613
Week 12, RMU: The same, n=100, 105, 101231121
Week 12, RMU: A little more often, n=100, 105, 101254
Week 12, RMU: Somewhat more often, n=100, 105, 101402
Week 12, RMU: Much more often, n=100, 105, 101210

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/116 (0.9%)26/116 (22.4%)
Vilanteral 25 µg OD—1/115 (0.9%)26/115 (22.6%)
Salmeterol 50 µg BID—0/116 (0%)21/116 (18.1%)
Most frequent serious events
Most frequent serious events
EventPlaceboVilanteral 25 µg ODSalmeterol 50 µg BID
AsthmaRespiratory, thoracic and mediastinal disorders0/1161/1150/116
Sudden deathGeneral disorders1/1160/1150/116
Most frequent other events
Most frequent other events
EventPlaceboVilanteral 25 µg ODSalmeterol 50 µg BID
NasopharyngitisInfections and infestations12/1169/1157/116
HeadacheNervous system disorders5/11610/1159/116
Upper respiratory tract infectionInfections and infestations8/1162/1152/116
Oropharyngeal painRespiratory, thoracic and mediastinal disorders7/1166/1152/116
Musculoskeletal painMusculoskeletal and connective tissue disorders0/1160/1155/116
PyrexiaGeneral disorders0/1164/1151/116

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboVilanteral 25 µg ODSalmeterol 50 µg BIDTotal
Mean41.7 ± 16.6441.0 ± 17.8141.1 ± 16.8441.3 ± 17.06
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVilanteral 25 µg ODSalmeterol 50 µg BIDTotal
Female596877204
Male574739143
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboVilanteral 25 µg ODSalmeterol 50 µg BIDTotal
African American/African Heritage115622
American Indian or Alaska Native374441122
Japanese/East Asian Heritage0011
White686668202
08

Study locations

34 sites
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Orlando, Florida 32822, United States
  • GSK Investigational Site
    Tallahassee, Florida 32308, United States
  • GSK Investigational Site
    Lawrenceville, Georgia 30046, United States
  • GSK Investigational Site
    Skillman, New Jersey 08558, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27607, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • GSK Investigational Site
    Chester, South Carolina 29706, United States
  • GSK Investigational Site
    Clinton, South Carolina 29325, United States
  • GSK Investigational Site
    Orangeburg, South Carolina 29118, United States
  • GSK Investigational Site
    Gauting, Bayern 82131, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60596, Germany
  • GSK Investigational Site
    Mainz, Rheinland-Pfalz 55131, Germany
  • GSK Investigational Site
    Grosshansdorf, Schleswig-Holstein 22927, Germany
  • GSK Investigational Site
    Callao, Lima Callao 2, Peru
  • GSK Investigational Site
    Lima 27, Lima Lima 27, Peru
  • GSK Investigational Site
    San Isidro, Lima Lima 27, Peru
  • GSK Investigational Site
    San Miguel, Lima Lima 32, Peru
  • GSK Investigational Site
    Lima, Lima 27, Peru
  • GSK Investigational Site
    Chrzanow, 32-500, Poland
  • GSK Investigational Site
    Krakow, 30-901, Poland
  • GSK Investigational Site
    Krakow, 31-024, Poland
  • GSK Investigational Site
    Krakow, 31-455, Poland
  • GSK Investigational Site
    Lublin, 20-552, Poland
  • GSK Investigational Site
    Dnipropetrovsk, 49027, Ukraine
  • GSK Investigational Site
    Dnipropetrovsk, 49074, Ukraine
  • GSK Investigational Site
    Donetsk, 83099, Ukraine
  • GSK Investigational Site
    Ivano-Frankivsk, 76018, Ukraine
  • GSK Investigational Site
    Kharkiv, 61037, Ukraine
  • GSK Investigational Site
    Kharkiv, 61124, Ukraine
  • GSK Investigational Site
    Kyiv, 03680, Ukraine
  • GSK Investigational Site
    Simferopol, 95043, Ukraine
  • GSK Investigational Site
    Yalta, 98603, Ukraine
09

References and documents

Publications

  • Lotvall J, Bateman ED, Busse WW, O'Byrne PM, Woodcock A, Toler WT, Jacques L, Goldfrad C, Bleecker ER. Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids. J Negat Results Biomed. 2014 Jun 13;13(1):9. doi: 10.1186/1477-5751-13-9. PubMed 24928338 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 2 years after primary completion. A results delay was requested in Jul 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2010
First posted
Aug 13, 2010
Start
Sep 1, 2010
Primary completionActual
Aug 1, 2011
CompletionActual
Aug 26, 2011
Results delay requested
Jul 26, 2012
Results first posted
Aug 26, 2013
Last update
Nov 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01181895
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 13, 2010
Start date
Sep 1, 2010
Primary completion
Aug 1, 2011
Completion
Aug 26, 2011
Results posted
Aug 26, 2013
Last update
Nov 8, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vilanterol

Start the discussion